These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 26376132)

  • 1. The emerging role of complement inhibitors in transplantation.
    Frémeaux-Bacchi V; Legendre CM
    Kidney Int; 2015 Nov; 88(5):967-73. PubMed ID: 26376132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab in renal transplantation.
    Legendre C; Sberro-Soussan R; Zuber J; Rabant M; Loupy A; Timsit MO; Anglicheau D
    Transplant Rev (Orlando); 2013 Jul; 27(3):90-2. PubMed ID: 23747093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():9-13. PubMed ID: 26988663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-complement therapy for glomerular diseases.
    Bomback AS
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):152-8. PubMed ID: 24602464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.
    Zuber J; Frimat M; Caillard S; Kamar N; Gatault P; Petitprez F; Couzi L; Jourde-Chiche N; Chatelet V; Gaisne R; Bertrand D; Bamoulid J; Louis M; Sberro Soussan R; Navarro D; Westeel PF; Frimat L; Colosio C; Thierry A; Rivalan J; Albano L; Arzouk N; Cornec-Le Gall E; Claisse G; Elias M; El Karoui K; Chauvet S; Coindre JP; Rerolle JP; Tricot L; Sayegh J; Garrouste C; Charasse C; Delmas Y; Massy Z; Hourmant M; Servais A; Loirat C; Fakhouri F; Pouteil-Noble C; Peraldi MN; Legendre C; Rondeau E; Le Quintrec M; Frémeaux-Bacchi V
    J Am Soc Nephrol; 2019 Dec; 30(12):2449-2463. PubMed ID: 31575699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM; Brophy PD
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement in renal transplantation: The road to translation.
    Jager NM; Poppelaars F; Daha MR; Seelen MA
    Mol Immunol; 2017 Sep; 89():22-35. PubMed ID: 28558950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients.
    Jordan SC; Choi J; Kahwaji J; Vo A
    Transplant Proc; 2016 Apr; 48(3):806-8. PubMed ID: 27234741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of complement inhibition in kidney transplantation.
    Legendre C; Sberro-Soussan R; Zuber J; Frémeaux-Bacchi V
    Br Med Bull; 2017 Dec; 124(1):5-17. PubMed ID: 29069327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
    Burbach M; Suberbielle C; Brochériou I; Ridel C; Mesnard L; Dahan K; Rondeau E; Hertig A
    Transplantation; 2014 Nov; 98(10):1056-9. PubMed ID: 24839895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the complement cascade: novel treatments coming down the pike.
    Thurman JM; Le Quintrec M
    Kidney Int; 2016 Oct; 90(4):746-52. PubMed ID: 27325183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent complement-mediated Hemolytic uremic syndrome after kidney transplantation.
    Obata S; Hullekes F; Riella LV; Cravedi P
    Transplant Rev (Orlando); 2024 Jul; 38(3):100857. PubMed ID: 38749097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecules Great and Small: The Complement System.
    Mathern DR; Heeger PS
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1636-50. PubMed ID: 25568220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement and kidney disease.
    Cook HT
    Curr Opin Nephrol Hypertens; 2013 May; 22(3):295-301. PubMed ID: 23508058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.
    Zimmerhackl LB; Hofer J; Cortina G; Mark W; Würzner R; Jungraithmayr TC; Khursigara G; Kliche KO; Radauer W
    N Engl J Med; 2010 May; 362(18):1746-8. PubMed ID: 20445192
    [No Abstract]   [Full Text] [Related]  

  • 16. Complement modulation in solid-organ transplantation.
    Touzot M; Obada EN; Beaudreuil S; François H; Durrbach A
    Transplant Rev (Orlando); 2014 Jul; 28(3):119-25. PubMed ID: 24996770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eculizumab in Renal Transplantation: A 2017 Update.
    Grenda R; Durlik M
    Ann Transplant; 2017 Sep; 22():550-554. PubMed ID: 28894081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics.
    Patriquin CJ; Kuo KHM
    Transfus Med Rev; 2019 Oct; 33(4):256-265. PubMed ID: 31703946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement inhibitors are not useful in secondary hemolytic uremic syndromes.
    Duineveld C; Wetzels JFM
    Kidney Int; 2019 Oct; 96(4):829-833. PubMed ID: 31543154
    [No Abstract]   [Full Text] [Related]  

  • 20. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.